Regeneration and repair of mesenchymal tissue using amelogenin

Abstract

A method of treating an injury to or a disease of a skeletal joint ligament is disclosed. The method comprises contacting the skeletal joint ligament or tendon of the subject with a therapeutically effective amount of amelogenin, wherein the amelogenin is not comprised in a scaffold, thereby treating the injury to or disease of the skeletal joint ligament or tendon.

1 - 22 . (canceled) 
     
     
         23 . Amelogenin for treating an injury to a skeletal joint ligament or a tendon wherein the amelogenin is not comprised in a scaffold. 
     
     
         24 . Mesenchymal stem cells (MSCs) which have been genetically modified to express amelogenin for treating an injury to a skeletal joint ligament or a tendon tear. 
     
     
         25 . Amelogenin for treating an injury to the meniscus, labrum or spinal intervertebral disc. 
     
     
         26 . The amelogenin of  claim 23 , wherein said amelogenin is expressed in a population of MSCs. 
     
     
         27 . The amelogenin of  claim 23 , wherein said amelogenin is human amelogenin. 
     
     
         28 . The amelogenin of  claim 27 , wherein said amelogenin comprises an amino acid sequence as set forth in SEQ ID NO: 1. 
     
     
         29 . The mesenchymal stem cells of  claim 24 , being isolated from bone marrow tissue. 
     
     
         30 . The mesenchymal stem cells of  claim 24 , wherein said amelogenin is expressed from an adenoviral vector. 
     
     
         31 . The amelogenin of  claim 25 , wherein said amelogenin is expressed in a population of MSCs. 
     
     
         32 . The amelogenin of  claim 24 , wherein said amelogenin is human amelogenin. 
     
     
         33 . The amelogenin of  claim 25 , wherein said amelogenin is human amelogenin. 
     
     
         34 . The amelogenin of  claim 32 , wherein said amelogenin comprises an amino acid sequence as set forth in SEQ ID NO: 1. 
     
     
         35 . The amelogenin of  claim 33 , wherein said amelogenin comprises an amino acid sequence as set forth in SEQ ID NO: 1. 
     
     
         36 . The amelogenin of  claim 26 , wherein said MSCs are isolated from bone marrow tissue. 
     
     
         37 . The amelogenin of  claim 26 , wherein said amelogenin is expressed from an adenoviral vector.